Our Lady of Mercy Medical Center   Report issue

Academic/Hospital Phase 2
Founded: Bronx NY United States (1884)

Organization Overview

First Clinical Trial
1997
NCT00003885
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

aldesleukin (Proleukin) (1 trial)

arsenic trioxide (trisenox) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Leukemia (Phase 2)

Lymphoma (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Preleukemia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2